Patients with acute myeloid leukemia (AML) in remission for over 3 years experience survival rates comparable with a matched cohort from the general population.
The FDA has granted orphan drug designation to ligufalimab, a CD47 monoclonal antibody, for treatment of acute myeloid ...
Ligufalimab receives FDA orphan drug designation for AML, showcasing promising efficacy and safety in treating hematologic ...
Researchers executed a phase 1b study to determine the safety and efficacy of venetoclax combined with a 7+3 chemotherapy regimen in treating acute myeloid leukemia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback